An Epigenetic Program Dictates MYC Amplification Dynamics that Promote Transient, Extrachromosomal and Inherited Genomic Events

Description

SUMMARY (147 words) MYC amplification is common and often extrachromosomal (ecDNA) in cancer. In order to define how MYC DNA copy gains arises from diploid genomes, we assessed whether epigenetic enzymes directly control focal MYC over-replication and amplification. We demonstrate that H3K4 methylation primes MYC for amplification by the H3K9/K36 tri-demethylase KDM4C, while the H3K36 tri-methyltransferase SETD2 restrains copy gains. These relationships are also observed in tumor datasets. SETD2 loss or inhibition promotes recruitment of catalytically active KDM4C, which initiates and drives stepwise MYC copy gains. Suppressing apoptosis or losing TP53 accelerates the emergence of higher-level MYC amplification events, including extrachromosomal circular ecDNAs (eccDNAs) and inherited copy gains. Non-transformed cells with these alterations are tumorigenic. Furthermore, KDM4C inhibition suppresses MYC amplification. These data define a chromatin-apoptotic axis directly controlling the initiation and progression of MYC amplification from diploid to hyper-amplification, while identifying biomarkers and therapeutic targets to constrain MYC-amplified tumors.

Steps to reproduce

See Methods in the manuscript for details. All large z-stack image slidebook files for each figure are available upon request due to storage space limits in this storage site.

Institutions

• Fox Chase Cancer Center

  Pennsylvania, Philadelphia

Categories

Funders

• National Institute of General Medical Sciences

  National Institutes of Health

  Maryland, Bethesda

  Grant ID: R35GM144131

Licence